Emsley 1995.
Methods | Allocation: randomised (no further description). Blindness: double (no further description). Duration: 6 weeks. Consent: not stated. Setting: multicentre, multinational. | |
Participants | Diagnosis:schizophrenia or schizophreniform disorder (DSM‐III‐R). N=183. Sex: 122M, 61F. Age: 15‐50 years. History: first‐episode. Exclusions: not stated | |
Interventions | 1. Risperidone: 2‐16 mg/day, an initial dose of 4mg/day was adjusted as required throughout the trial. N=99. 2. Haloperidol: 1‐16 mg/day, an initial dose of 4mg/day was adjusted as required throughout the trial. N=84. | |
Outcomes | Clinical improvement: >50% in PANSS.
Adverse effects: various observed effects.
Leaving the study early. Unable to use ‐ Global effect: CGI score (no SD). Mental state BPRS ‐ PANSS derived, PANSS (no SD). Physiological monitoring: ECG, lab tests (no data) Adverse effects: ESRS (no SD). |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |